Plitidepsin 1.5 mg/day

DRUG2 trials

Sponsors

PharmaMar, Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Conditions

COVID-19Long COVIDLong COVID SyndromePersistent COVID ConditionPersistent COVID-19Post COVID-19 Condition

Phase 1

Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19

CompletedNCT04382066

PharmaMarCOVID-19

Start: 2020-05-12End: 2020-11-26Updated: 2022-08-23

Phase 2

Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)

Active, not recruitingNCT06766825

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaLong COVID, Long COVID Syndrome, Persistent COVID-19 +2

Start: 2025-02-07End: 2026-09-10Target: 90Updated: 2026-07-14

Related Papers

Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysis

Frontiers in Cellular and Infection Microbiology2023-02-229 citations

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

Life Science Alliance2022-01-1050 citations